These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 10608107)
61. Aspects of medical communications in the United Kingdom. Higgins DG Drug Inf J; 1975; 9(1):32-7. PubMed ID: 10236955 [No Abstract] [Full Text] [Related]
62. [Drug companies and continuing education]. Hotvedt R Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2043. PubMed ID: 16100551 [No Abstract] [Full Text] [Related]
63. Beyond the naïve "no-see": ethical prescribing and the drive for pharmaceutical transparency. Oldani M PM R; 2009 Jan; 1(1):82-6. PubMed ID: 19627878 [No Abstract] [Full Text] [Related]
64. [Drug industry's "offers" to health personnel]. Møller N Ugeskr Laeger; 2007 Nov; 169(47):4081. PubMed ID: 18087788 [No Abstract] [Full Text] [Related]
65. [Misuse of literature references in advertising]. Jørgen E Ugeskr Laeger; 2004 Nov; 166(48):4393; author reply 4393-4. PubMed ID: 15587640 [No Abstract] [Full Text] [Related]
66. Promoting and advertising therapeutic goods. Trade Practices Commission report on self-regulation. Moulds RF Med J Aust; 1992 Oct; 157(8):513-4. PubMed ID: 1479969 [No Abstract] [Full Text] [Related]
67. New inconvenient trend in advertising medicine. Salunke AZ J Indian Med Assoc; 1994 Nov; 92(11):381. PubMed ID: 7890949 [No Abstract] [Full Text] [Related]
68. [Viewpoint of the medical profession on drug information]. Bejerot N; Ortengren J Lakartidningen; 1965 Nov; 62(45):3756-73. PubMed ID: 5868627 [No Abstract] [Full Text] [Related]
70. The ethics of identifying and treating psychosis early. Agius M; Bradley V; Ryan D; Zaman R Psychiatr Danub; 2008 Mar; 20(1):93-6. PubMed ID: 18376339 [No Abstract] [Full Text] [Related]
71. At risk mental states. Filaković P; Degmecić D; Koić E; Benić D Psychiatr Danub; 2008 Mar; 20(1):97. PubMed ID: 18376340 [No Abstract] [Full Text] [Related]
72. [Who is to be trusted? On press reporters' assignments and agendas]. Nyrén O Lakartidningen; 2002 Dec; 99(50):5110-2. PubMed ID: 12572305 [No Abstract] [Full Text] [Related]
73. Drug promotion and scientific exchange. Wilbur RS N Engl J Med; 1992 Jan; 326(2):133-4. PubMed ID: 1550609 [No Abstract] [Full Text] [Related]
74. Psychology in the prescription era: building a firewall between marketing and science. Antonuccio DO; Danton WG; McClanahan TM Am Psychol; 2003 Dec; 58(12):1028-43. PubMed ID: 14664691 [TBL] [Abstract][Full Text] [Related]
75. [Physicians and drug industry: attitudes and practice]. Aasland OG; Førde R Tidsskr Nor Laegeforen; 2004 Oct; 124(20):2603-6. PubMed ID: 15534631 [TBL] [Abstract][Full Text] [Related]
76. Encounters between physicians and pharmaceutical sales representatives. Yarnall SR Am J Med; 2000 Apr; 108(5):431-2. PubMed ID: 10759103 [No Abstract] [Full Text] [Related]
77. Who has the ultimate responsible for publishing clinical research results? Wilde H; Sitprija V J Med Assoc Thai; 2001 Aug; 84(8):1217-20. PubMed ID: 11758861 [No Abstract] [Full Text] [Related]
79. [Central management of all drug information? Information of industries should be decreased strongly. There should be fewer consultants and they should be given a new role]. Karlsson Y Nord Med; 1977 Nov; 92(11):284-5. PubMed ID: 917783 [No Abstract] [Full Text] [Related]
80. Physicians and drug company sales representatives. Davis GF Am J Med; 2000 Apr; 108(5):432-3. PubMed ID: 10759104 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]